We established a genetic model for predicting psoriasis susceptibility based on three candidate cuproptosis-related genes (CRGs), MTF1, ATP7B, and SLC31A1, and found that patients can gain clinical benefits based on this model. This evidence concerns the gene MTF1 and psoriasis.